

# Bruno Emond

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2423512/publications.pdf>

Version: 2024-02-01

44  
papers

639  
citations

758635

12  
h-index

610482

24  
g-index

44  
all docs

44  
docs citations

44  
times ranked

562  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate. <i>Drugs - Real World Outcomes</i> , 2020, 7, 19-29.	0.7	174
2	Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics. <i>Clinical Therapeutics</i> , 2017, 39, 1972-1985.e2.	1.1	80
3	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016, 22, 446-458.	1.3	73
4	Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. <i>BMC Psychiatry</i> , 2017, 17, 207.	1.1	37
5	Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. <i>Current Medical Research and Opinion</i> , 2017, 33, 1763-1772.	0.9	22
6	Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2022, 25, 457-468.	1.0	22
7	Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. <i>Epilepsia Open</i> , 2019, 4, 581-592.	1.3	19
8	Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 763-775.e2.	0.2	18
9	An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. <i>Current Medical Research and Opinion</i> , 2020, 36, 1313-1323.	0.9	18
10	Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. <i>Current Medical Research and Opinion</i> , 2019, 35, 407-416.	0.9	15
11	Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors. <i>Current Medical Research and Opinion</i> , 2019, 35, 1751-1759.	0.9	14
12	Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study. <i>Current Medical Research and Opinion</i> , 2021, 37, 665-674.	0.9	14
13	Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bicitegravir/emtricitabine/tenofovir alafenamide in the United States. <i>Current Medical Research and Opinion</i> , 2022, 38, 287-298.	0.9	14
14	Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. <i>PharmacoEconomics - Open</i> , 2019, 3, 177-188.	0.9	13
15	Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study. <i>BMC Rheumatology</i> , 2020, 4, 16.	0.6	12
16	Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bicitegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 88-98.	0.6	12
17	Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. <i>Current Medical Research and Opinion</i> , 2018, 34, 1125-1133.	0.9	8
18	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 1-15.	3.0	8

#	ARTICLE	IF	CITATIONS
19	An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 140-147.	1.2	7
20	Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. <i>Current Medical Research and Opinion</i> , 2018, 34, 1377-1388.	0.9	6
21	Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. <i>Current Medical Research and Opinion</i> , 2020, 36, 2009-2018.	0.9	6
22	Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e959-e971.	0.2	6
23	Real-world treatment sequencing and healthcare costs among CLL/SLL patients treated with venetoclax. <i>Current Medical Research and Opinion</i> , 2021, 37, 1409-1420.	0.9	5
24	Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. <i>BMC Endocrine Disorders</i> , 2017, 17, 32.	0.9	4
25	Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. <i>Current Medical Research and Opinion</i> , 2018, 34, 1099-1115.	0.9	4
26	Economic burden of treatment failure in chronic lymphocytic leukemia patients. <i>Current Medical Research and Opinion</i> , 2018, 34, 1135-1142.	0.9	4
27	Treatment Patterns Among Patients With Mantle Cell Lymphoma and Comparison of Healthcare Resource Utilization and Costs Among Relapsed/Refractory Patients Treated With Ibrutinib or Chemoimmunotherapy: A Real-world Retrospective Study. <i>Clinical Therapeutics</i> , 2021, 43, 1285-1299.	1.1	4
28	Real-World Analysis of Weight Gain and Body Mass Index Increase Among Patients with HIV-1 Using Antiretroviral Regimen Containing Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Neither in the United States. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, 39-49.	0.6	3
29	Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 129-141.	0.5	2
30	Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 88-98.	0.6	2
31	Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study. <i>Journal of Health Economics and Outcomes Research</i> , 2021, 8, 88-98.	0.6	2
32	Clinical and Economic Burden of Tumor Lysis Syndrome Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2021, 138, 4030-4030.	0.6	2
33	Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. <i>Current Medical Research and Opinion</i> , 2022, 38, 613-627.	0.9	2
34	Incidence and economic burden of respiratory syncytial virus among adults in the United States: A retrospective analysis using 2 insurance claims databases. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, , 1-13.	0.5	2
35	Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 117-128.	0.5	1
36	Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18693-e18693.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Front-Line Ibrutinib Treatment Is Associated with Longer Time to Next Treatment, Net Total Cost Reduction, and Lower Healthcare Resource Utilization Compared to Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 2306-2306.	0.6	1
38	Real-World Persistence and Time to Next Treatment with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. <i>Blood</i> , 2021, 138, 4112-4112.	0.6	1
39	HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, HSR22-153.	2.3	1
40	Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, 291-291.	0.8	0
41	Real-world healthcare resource utilization (HRU)/costs associated with venetoclax treatment among chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19354-e19354.	0.8	0
42	Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19408-e19408.	0.8	0
43	Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following First-Line Ibrutinib. <i>Blood</i> , 2021, 138, 4016-4016.	0.6	0
44	HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, HSR22-173.	2.3	0